Pharmacy Podcast Network

In this episode of MaternalRx, Dr. Elif Polat, MD, researcher, endometriosis advocate, and Turkey representative for Worldwide EndoMarch, joins Dr. Danielle Plummer to discuss the often misunderstood and deeply complex condition of endometriosis. Dr. Polat unpacks what endometriosis truly is, explaining how it’s both an inflammatory and hormone-dependent disease that can affect any organ in the body, even beyond the reproductive system. She reveals why diagnosis can take up to ten years, why standard tests often miss it, and how its symptoms can extend far beyond pelvic pain, sometimes presenting in surprising ways. The conversation dives into how endometriosis impacts fertility, pregnancy, and the risk of ectopic pregnancy, and clarifies when tools like hysteroscopy may be appropriate. Dr. Polat also dispels common myths, such as the belief that pregnancy or hysterectomy can cure the disease, and emphasizes the importance of continued research and advocacy. Listeners will gain insight into how endometriosis affects not only patients but their families and communities, and how global initiatives like Worldwide EndoMarch (@endomarch) are driving awareness and change. Stay through the end for Dr. Plummer’s “Final Thoughts,” where she reflects on how pharmacists can better support patients through empathy, education, and collaboration. Connect with Dr. Elif Polat: www.linkedin.com/in/elif-polat-md-a20a0b18b/ Connect with WorldWide EndoMarch Instagram: @wwendomarch https://endomarch.org/ Connect with Dr. Plummer: www.linkedin.com/in/daniellerplummer/

In this episode of Pharmacist-Prescribed, hosts Mary Kucek and Devin Bustin, MD, explore the mission behind PRISM and the urgent need for pharmacist-led clinical services. They discuss the growing gaps in healthcare access, the underutilization of pharmacists as providers, and how technology can safely enable care right inside community pharmacies. Learn more or request a demo at getprismrx.com.

Tune in as Jon Grice, Steve Maki, Emily Byrne, and Austin Wang share their experiences with Outcomes—along with personal stories about what inspired them to enter the pharmacy field and why they’re passionate about the profession.

Special Guest: Ilisa B.G. Bernstein, PharmD, JD CEO & Co-founder Johny Kello | MatchRX Topic: DSCSA Compliance, Industry Readiness & the Future of Pharmacy Safety Episode Overview This week on TWIRx, Johny Kello welcomes one of the 50 Most Influential People in Pharmacy, Ilisa B.G. Bernstein, PharmD, JD, to break down the current state of DSCSA compliance as the industry approaches the critical November 2025 enforcement deadline. With decades of leadership in pharmacy practice, regulatory policy, and national advocacy, Dr. Bernstein brings unmatched clarity to what pharmacies must do now — and how the right technology partnerships can keep them operational, efficient, and fully compliant. Together, Johny and Dr. Bernstein discuss why DSCSA readiness remains one of the most pressing challenges for independent and community pharmacies — from data verification and product tracing to avoiding shipment rejections, workflow disruptions, and audit exposure. Johny Kello LinkedIn: https://www.linkedin.com/in/johny-kello/   Ilisa B.G. Bernstein, PharmD, JD LinkedIn: https://www.linkedin.com/in/ilisa-bernstein-b67222174/ Learn more: https://www.matchrx.com/ Featured guest: Dr. Jordyn Nordé, PharmD, MBA, is a forward-thinking clinical pharmacist and community leader based in St. Louis who combines advanced clinical training with business acumen to drive impact in underserved populations. With experience in ambulatory care and medication management for conditions like hypertension, diabetes and pain, she is also the founder of an initiative bringing minority pharmacy professionals together through mentorship, entrepreneurship and wellness conversations. Her dual credentials enable her to bridge healthcare, professional development and advocacy — positioning her as an emerging influencer in pharmacy practice transformation. LinkedIn: https://www.linkedin.com/in/jordynnorde/

In this edition of Essential, we’ve got updates on some big compounding news — like the FDA’s long-overdue decision to remove the boxed warning from some menopause hormone-replacement therapy drugs. (And yes, that’s important for compounding pharmacists!) We also look at the hubbub at FDA over what (allegedly) was behind the decision that would have effectively banned compounding with desiccated thyroid extract, plus some stories from the states, and more. This month’s deep dive: Mythbusting, compounded-GLP-1 style! What have the big drugmakers been saying, and how much of it is true? They’re spreading stories, but our experts put them to the test. Don’t miss out! Links Join APC today: https://a4pc.org/membership  FDA to remove boxed warning from HRT medications: https://archive.ph/R8DJD  An example of what appears to be an op-ed pushed by a pharma company. The writer, a “former healthcare professional,”doesn’t appear to exist: https://archive.ph/OPNWr  Find a legitimate, licensed compounding pharmacy: https://a4pc.org/isitlegit  Benefits of becoming an APC PFM: https://a4pc.org/pfm 

In this episode of the NASP Podcast, Sheila Arquette, President & CEO of NASP, speaks with Matthew G. Bowles, PharmD, MBA, CSP, Pharmacy Clinical Team Lead with Vanderbilt Specialty Pharmacy, Vanderbilt Health, and lead author on the study “Getting to specialty treatment in dermatologic inflammatory conditions: Treatment requirements and patient journey,” published February 2025 in the Journal of Managed Care & Specialty Pharmacy. They discuss the reasons for conducting and results of the study, as well as the impacts the study may have on specialty and managed care pharmacy.

In this episode of Tech Trends by PrimeRx, we continue our deep dive into the evolving world of pharmacy technology. Building on the momentum from our previous discussion—where we explored the shifting landscape of pharmacy tech innovation—we now turn our focus to one of the most urgent challenges facing independent and community pharmacies: making sense of inventory and purchase data. Dr. Matthew Song joins us to break down why automation is no longer optional and how data intelligence is transforming pharmacy operations. With rising costs, shrinking margins, and increasing administrative demands, the ability to automate and optimize data workflows is becoming a competitive advantage. Dr. Song sets the stage by examining how automated systems offer unprecedented visibility into a pharmacy’s financial and clinical activity. Today’s modern PMS platforms, including PrimeRx, go far beyond dispensing—they automatically collect, analyze, and interpret operational data. Throughout the episode, we’ll uncover how automation identifies top payers, high-impact drugs, key prescribers, patient adherence trends, and more. These insights help pharmacy leaders make informed decisions around purchasing, contracting, staffing, and patient care. Listeners will also gain actionable takeaways tied directly to real-time metrics, including dashboards that connect inventory fluctuations to financial performance. Dr. Song explains how automation eliminates manual entry errors, accelerates purchasing decisions, and helps pharmacies avoid costly stockouts or overstocking. From surfacing seasonal medication trends to pinpointing high-volume PBMs or top-referring providers, this episode demonstrates the power of transforming raw data into strategic intelligence. Stay tuned through the end as we tease what’s next on the horizon—AI-driven predictive inventory management and the next evolution in pharmacy automation.

Welcome to the Pharmacy Podcast Network's coverage of the NCPA 2025 Post Show! The NCPA annual conference is the trailblazer for community pharmacy, bringing together the pharmacy community. Our host Todd Eury, founder and CEO of the Pharmacy Podcast Network, took the microphone to the action right on the show floor capturing exclusive conversations with attendees, pharmacy students, keynote speakers, vendors, and more!  Thank you YARAL Pharma for sponsoring this coverage of the NCPA Post Show!  Visit https://yaralpharma.com/

In this episode of The Pediatric Pharmacist Review, we explore the phenomenon of seasonal affective disorder (SAD) and its relevance to children, adolescents, and families. Our guest, Tim Horton, is a seasoned psychiatric nurse‑practitioner (APRN, CNP) and founder of PeopleFirst Clinic in Woodbury, Minnesota, where he specializes in holistic, medication‑management and therapy‑integrated care for youth and adults. With his unique background in pediatric mental health, patient‑centered approaches, and collaborative provider work, Tim brings deep insight into how biological and environmental factors converge in seasonal depression—and what practical actions caregivers and clinicians can take to mitigate its impact. Key Discussion Points: Biological & Environmental Contributors: We unpack how changes in daylight exposure, circadian rhythm shifts, neurotransmitter variations (serotonin, melatonin), and geographic/seasonal factors contribute to SAD in children and teens. Lifestyle & Environmental Interventions: Tim and I discuss actionable strategies such as structured light‑exposure (dawn simulators, 10,000 lux boxes), daily outdoor activity, consistent sleep schedules, and nutritional supports (timing of meals, nutrient‑dense foods, healthy fats) to reduce symptom severity. Treatment Options & Efficacy: We review standard of care for SAD—starting with behavioral and lifestyle measures, then progressing to light therapy and pharmacologic treatment (SSRIs, SNRIs, augmentation) when needed, including considerations unique to pediatric populations. Vitamin D and Seasonal Depression: We examine the evidence linking vitamin D deficiency with increased SAD risk, discuss screening thresholds in younger patients, supplementation strategies, and how this fits into a broader preventive mindset. Preventive Measures Ahead of Winter: Tim outlines a pre‑winter readiness plan—adjusting indoor lighting, optimizing outdoor daylight exposure, establishing routine exercise, reinforcing healthy diet patterns, and monitoring early warning signs for a proactive response. Misconceptions and Under‑Recognition: We address common myths—such as SAD only occurring in extreme northern latitudes, or that “it’s just the blues” and will self‑resolve—highlighting how under‑recognition in pediatric settings can delay helpful intervention. Resources & Links: Tim Horton LinkedIn: https://www.linkedin.com/in/tim-horton-248858359/ PeopleFirst Clinic: https://www.peoplefirstmn.com/

Special Feature:    Andrew Crawford, Vice President at Keysource talks with TWIRx host Todd Eury about the direct to patient market (Direct to Consumer, DTC) expected to hit $21 billion this year. Pharmacy is evolving fast. When DTC brands move in, pharmacies have a choice...compete or collaborate. Some manufacturers are selling directly to patients at discounted cash prices and cutting out traditional intermediaries. The model is projected to grow 9% a year through 2030, with pharma support services expected to nearly double from $3.2B to $5.7B by 2030.  Driven by cost pressure and new legislation, manufacturers are moving quickly. It is creating more transparency but patients still need guidance, trust, and human care. Pharmacy is being redefined as the bridge that keeps care personal, safe, and local. It is not being replaced, but what will it look like in 10 years? TWIRx News:    Pharmacy student shot, killed by friend who became paranoid after they smoked pot together, documents say - from WMTV/Gray News  https://www.wowt.com/2025/11/11/pharmacy-student-shot-killed-by-friend-who-became-paranoid-after-they-smoked-pot-together-documents-say/  Why Guardian Pharmacy Services Stock Was on a Tear Tuesday - by Motley Fool / Yahoo Finance  https://finance.yahoo.com/news/why-guardian-pharmacy-services-stock-202435130.html Metformin May Diminish the Cardiometabolic Benefits of Exercise https://www.pharmacytimes.com/view/metformin-may-diminish-the-cardiometabolic-benefits-of-exercise Today's TWIRx is sponsored by YARAL Pharma & SureCost